Abstract
Abnormal luteal function is a common issue in assisted reproduction techniques associated with ovarian stimulation probably due to low levels of LH in the middle and in the late luteal phase. This defect seems to be associated with supraphysiological steroid levels at the end of follicular phase. The luteal phase insufficiency has not got a diagnostic test which has proven reliable in a clinical setting. Luteal phase after ovarian stimulation becomes shorter and insufficient, resulting in lower pregnancy rates. Luteal phase support with progesterone or hCG improves pregnancy outcomes and no differences are found among different routes of administration. However, hCG increases the risk of ovarian hyperstimulation syndrome. In relation to the length of luteal support, the day of starting it remains controversial and it does not seem necessary to continue once a pregnancy has been established. After GnRHa triggering ovulation, intensive luteal support or hCG bolus can overcome the defect in luteal phase, but more studies are needed to show the LH utility as support.
Keywords: Assisted reproduction treatments, GnRH agonist triggering, hCG, LH, luteal phase support, progesterone.
Current Drug Targets
Title:Treatment of Luteal Phase Defects in Assisted Reproduction
Volume: 14 Issue: 8
Author(s): Elkin Munoz, Esther Taboas, Susana Portela, Jesus Aguilar, Iria Fernandez, Luis Munoz and Ernesto Bosch
Affiliation:
Keywords: Assisted reproduction treatments, GnRH agonist triggering, hCG, LH, luteal phase support, progesterone.
Abstract: Abnormal luteal function is a common issue in assisted reproduction techniques associated with ovarian stimulation probably due to low levels of LH in the middle and in the late luteal phase. This defect seems to be associated with supraphysiological steroid levels at the end of follicular phase. The luteal phase insufficiency has not got a diagnostic test which has proven reliable in a clinical setting. Luteal phase after ovarian stimulation becomes shorter and insufficient, resulting in lower pregnancy rates. Luteal phase support with progesterone or hCG improves pregnancy outcomes and no differences are found among different routes of administration. However, hCG increases the risk of ovarian hyperstimulation syndrome. In relation to the length of luteal support, the day of starting it remains controversial and it does not seem necessary to continue once a pregnancy has been established. After GnRHa triggering ovulation, intensive luteal support or hCG bolus can overcome the defect in luteal phase, but more studies are needed to show the LH utility as support.
Export Options
About this article
Cite this article as:
Munoz Elkin, Taboas Esther, Portela Susana, Aguilar Jesus, Fernandez Iria, Munoz Luis and Bosch Ernesto, Treatment of Luteal Phase Defects in Assisted Reproduction, Current Drug Targets 2013; 14 (8) . https://dx.doi.org/10.2174/1389450111314080002
DOI https://dx.doi.org/10.2174/1389450111314080002 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Related Books
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Platelet Turnover in Atherothrombotic Disease
Current Pharmaceutical Design Mitochondria as a Target for Exercise-Induced Cardioprotection
Current Drug Targets ACE2-Ang-(1-7)-Mas Axis in Brain: A Potential Target for Prevention and Treatment of Ischemic Stroke
Current Neuropharmacology Restoring the Dysfunctional Endothelium
Current Pharmaceutical Design Lipid Rafts and Redox Regulation of Cellular Signaling in Cholesterol Induced Atherosclerosis
Current Cardiology Reviews Tracking the Mesenchymal Stem Cell Fate After Transplantation Into the Infarcted Myocardium
Current Stem Cell Research & Therapy Is Age of 80 Years a Threshold for Carotid Revascularization?
Current Cardiology Reviews The Biochemical and Physical Process of Fibrinolysis and Effects of Clot Structure and Stability on the Lysis Rate
Cardiovascular & Hematological Agents in Medicinal Chemistry Clinical Applications of Cardiovascular Magnetic Resonance
Current Pharmaceutical Design Notch Signaling in Cardiovascular Disease and Calcification
Current Cardiology Reviews Role of Mechanical Stress in Monocytes / Macrophages: Implications for Atherosclerosis
Current Vascular Pharmacology Liver X Receptors: Potential Novel Targets in Cardiovascular Diseases
Current Drug Targets - Cardiovascular & Hematological Disorders The Role of P2X Receptors in Bone Biology
Current Medicinal Chemistry Novel Drug Targets for the Treatment of Cardiac Diseases
Current Pharmacogenomics and Personalized Medicine Oral Infection and Vascular Disease
Vascular Disease Prevention (Discontinued) Lipid Management for the Prevention of Cardiovascular Disease
Current Pharmaceutical Design Kupffer Cell-Dependent Signaling in Thyroid Hormone Calorigenesis: Possible Applications for Liver Preconditioning
Current Signal Transduction Therapy VDAC1 as a Player in Mitochondria-Mediated Apoptosis and Target for Modulating Apoptosis
Current Medicinal Chemistry Antisense Therapy for Cardiovascular Diseases
Current Pharmaceutical Design Mitophagy and Disease: New Avenues for Pharmacological Intervention
Current Pharmaceutical Design